KPL-716-C201: A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis

Dermatology

To evaluate the efficacy of subcutaneous (SC) KPL-716 in reducing pruritis in subjects with moderate to severe PN experiencing severe itching.

Principal Investigator(s)

Dr. Jonathan Silverberg MD, PHD, MPH

Request Information

First Name

Last Name

Email Address

Confirm email

Phone Number

Address

Address 2

City/Town

State/Province

ZIP/Postal Code

Comments / Questions

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.